# Filing Detail

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0000950170-24-127839
Filing Date
2024-11-18
Accepted
2024-11-18 12:03:25
Documents
90
Period of Report
2023-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q/A | rgen-20230630.htm iXBRL | 10-Q/A | 3692845
2 | EX-31.1 | rgen-ex31_1.htm | EX-31.1 | 14910
3 | EX-31.2 | rgen-ex31_2.htm | EX-31.2 | 14903
4 | EX-32.1 | rgen-ex32_1.htm | EX-32.1 | 18811
| Complete submission text file | 0000950170-24-127839.txt |  | 17656897

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | rgen-20230630.xsd | EX-101.SCH | 1746538
93 | EXTRACTED XBRL INSTANCE DOCUMENT | rgen-20230630_htm.xml | XML | 4655572

Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 000-14656 | Film No.: 241470423
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)